直肠系膜脂肪面积的定量评估:中低位直肠癌患者的新预后生物标志物
该研究纳入2011年接受根治性手术的中低位直肠癌患者,术前腹盆腔CT测量直肠系膜脂肪面积(MFA)和内脏脂肪面积(VFA),按5年随访有无复发分为A组(复发,42例)和B组(无复发,155例)。多因素Cox回归显示MFA(OR=0.426,p=0.010)、TNM分期(p=0.027)和围手术期并发症分级(p=0.028)组间差异显著,BMI和VFA无显著差异;MFA≥10 cm²患者无病生存期显著长于MFA<10 cm²者(p=0.021),总生存期无显著差异。结论认为MFA是预测根治性手术后中低位直肠癌患者无病生存期的独立生物标志物。
要点
- 术前CT测量的直肠系膜脂肪面积(MFA)是预测中低位直肠癌根治术后无病生存期的独立生物标志物。
- MFA≥10 cm²患者无病生存期显著长于MFA<10 cm²患者(p=0.021),总生存期无显著差异。
- MFA可在术前CT上简便计算,有助于术前评估直肠癌患者预后。
核心结论
- MFA是接受根治性手术的中低位直肠癌患者无病生存期的独立生物标志物。
- MFA与中低位直肠癌患者预后相关。
- MFA可在术前CT扫描上简便计算。
- 术前预测癌症患者预后具有重要意义。
研究设计与样本
- 研究类型为回顾性队列研究,纳入2011年接受术前腹盆腔CT和根治性手术的中低位直肠癌患者,随访5年。
- 按肿瘤复发与否分为A组(复发,42例)和B组(无复发,155例)。
- 术前CT测量内脏脂肪面积(VFA)和直肠系膜脂肪面积(MFA),采用Youden指数计算截断值。
- 采用单因素和多因素回归分析(纳入BMI、VFA、MFA)筛选有意义的预后生物标志物,并用Kaplan-Meier法和log-rank检验验证。
关键影像表现/征象
- 术前CT可测量直肠系膜脂肪面积(MFA)和内脏脂肪面积(VFA)。
诊断标准与关键数值
- 采用Youden指数计算的截断值:BMI为25 kg/m²,VFA为130 cm²,MFA为10 cm²。
- 多因素Cox回归分析显示MFA(OR=0.426,p=0.010)、TNM分期(p=0.027)和围手术期并发症分级(p=0.028)在组间差异显著。
- BMI和VFA在组间无显著差异。
- Kaplan-Meier法log-rank检验显示,MFA≥10 cm²患者无病生存期显著长于MFA<10 cm²患者(p=0.021),总生存期无显著差异。
临床应用与阅片要点
- 术前CT测量直肠系膜脂肪面积(MFA)可用于预测中低位直肠癌根治术后无病生存期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate the impact of mesorectal fat area (MFA) on oncologic outcomes in patients with mid-to-lower rectal cancer who received curative-intent surgery.
METHODS: Patients with mid-to-lower rectal cancer who underwent preoperative abdominopelvic computed tomography (CT) and curative-intent surgery in 2011 were divided into two groups by tumour recurrence (group A) or no recurrence (group B) during a 5-year follow-up. Visceral fat area (VFA) and MFA were measured on preoperative CT and cutoff values were calculated using the Youden index. Univariate and multivariate regression analyses including BMI, VFA, and MFA were performed to investigate meaningful prognostic biomarkers. The Kaplan-Meier method with log-rank testing was used to validate prognostic biomarkers.
RESULTS: Group A contained 42 patients and group B had 155 patients. Cutoff values were 25 kg/m2 for BMI, 130 cm2 for VFA, and 10 cm2 for MFA using the Youden index. On multivariate Cox regression analysis, MFA (odds ratio [OR] = 0.426, p = 0.010), TNM stage (p = 0.027), and perioperative complication grade (p = 0.028) were significantly different between groups. BMI and VFA did not show significant differences. By the Kaplan-Meier method with log-rank testing, disease-free survival (DFS) was significantly longer in patients with MFA ≥10 cm2 compared to patients with MFA <10 cm2 (p = 0.021), with no significant difference in overall survival (OS).
CONCLUSIONS: MFA was an independent biomarker for predicting DFS in patients who underwent curative-intent surgery for mid-to-lower rectal cancer.
KEY POINTS: • Mesorectal fat area is associated with the prognosis of rectal cancer patients. • Mesorectal fat area can be calculated easily in pre-operative CT scan. • Predicting prognosis of the cancer patient before operation is important.
引用
- Yoon J, Chung YE, Lim JS, et al. Quantitative assessment of mesorectal fat: new prognostic biomarker in patients with mid-to-lower rectal cancer. Eur Radiol. 2018. PMID: 30229270. doi:10.1007/s00330-018-5723-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。